BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 7531616)

  • 21. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
    Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide.
    Steplewski Z; Lubeck MD; Scholz D; Loibner H; McDonald Smith J; Koprowski H
    In Vivo; 1991; 5(2):79-83. PubMed ID: 1768791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of antibody isotype on passive serotherapy of lymphoma.
    Denkers EY; Badger CC; Ledbetter JA; Bernstein ID
    J Immunol; 1985 Sep; 135(3):2183-6. PubMed ID: 2862210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
    Flieger D; Renoth S; Beier I; Sauerbruch T; Schmidt-Wolf I
    Cell Immunol; 2000 Aug; 204(1):55-63. PubMed ID: 11006018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
    de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
    Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
    Berinstein N; Levy R
    J Immunol; 1987 Aug; 139(3):971-6. PubMed ID: 3496394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of liposomes containing sodium butyrate conjugated with anti-CD19 monoclonal antibody on in vitro and in vivo growth of malignant lymphoma.
    Watanabe M; Pesando JM; Hakomori S
    Cancer Res; 1990 Jun; 50(11):3245-8. PubMed ID: 1692257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
    Christiaansen JE; Sears DW
    Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
    Kaminski MS; Kitamura K; Maloney DG; Campbell MJ; Levy R
    J Immunol; 1986 Feb; 136(3):1123-30. PubMed ID: 3484499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
    Hayden-Ledbetter MS; Cerveny CG; Espling E; Brady WA; Grosmaire LS; Tan P; Bader R; Slater S; Nilsson CA; Barone DS; Simon A; Bradley C; Thompson PA; Wahl AF; Ledbetter JA
    Clin Cancer Res; 2009 Apr; 15(8):2739-46. PubMed ID: 19351771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies of IPO series against B cell differentiation antigens in leukemia and lymphoma immunophenotyping.
    Sidorenko SP; Vetrova EP; Yurchenko OV; Berdova AG; Shlapatskaya LN; Gluzman DF
    Neoplasma; 1992; 39(1):3-9. PubMed ID: 1528302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model.
    Velders MP; van Rhijn CM; Briaire IH; Fleuren GJ; Warnaar SO; Litvinov SV
    Cancer Res; 1995 Oct; 55(19):4398-403. PubMed ID: 7671252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
    Watanabe M; Ohishi T; Kuzuoka M; Nudelman ED; Stroud MR; Kubota T; Kodairo S; Abe O; Hirohashi S; Shimosato Y
    Cancer Res; 1991 Apr; 51(8):2199-204. PubMed ID: 1706961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens.
    Dhein J; Daniel PT; Trauth BC; Oehm A; Möller P; Krammer PH
    J Immunol; 1992 Nov; 149(10):3166-73. PubMed ID: 1431095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.